Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) By Investing.com

SAN DIEGO, Jan. 20, 2025 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 20, 2025, the Human Capital Management Committee of Avidity’s Board of Directors granted a non-qualified stock option award to purchase an aggregate of 10,500 shares of its common stock and 5,250 restricted stock units (“RSUs”) to one (1) new non-executive employee under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the “2022 Inducement Plan”). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Avidity, or following a bona…